Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up (Cingal17-02)
Trial Extension Protocol to Add a 39 Week Follow Up to Cingal 16-02, a Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection of Cingal to Provide Symptomatic Relief of Knee Osteoarthritis
Sponsor: Anika Therapeutics, Inc.
This PHASE3 trial investigates Knee Osteoarthritis and is currently completed. Anika Therapeutics, Inc. leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jun 2023 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE3
Status: Enrolling By Invitation → Completed
-
Jan 2018 — Oct 2018 [monthly]
Enrolling By Invitation PHASE3
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anika Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bialystok, Poland , Bielsko-Biala, Poland , Budapest, Hungary , Debrecen, Hungary , Gliwice, Poland , Kiskunfélegyháza, Hungary , Krakow, Poland , Lodz, Poland , Tata, Hungary , Torun, Poland and 2 more locations